Table 6.

Multivariate analyses predicting survival in the validation cohort

Risk factors	n	PFS	P	OS	P
		HR (95% CI)		HR (95% CI)
Age			0.876		0.267
≤50 years	23	Referent		Referent
>50 years	48	0.95 (0.47–1.91)		0.61 (0.25–1.47)
FIGO stage			0.045		0.013
I–II	13	Referent		Referent
III–IV	58	1.407 (1.17–1.98)		2.26 (1.09–3.75)
Histotype			0.838		0.113
Type I	21	Referent		Referent
Type II	49	1.08 (0.54–2.16)		1.49 (1.21–3.18)
Grade			0.609		0.234
Low	11	Referent		Referent
Medium–high	60	1.78 (1.30–3.04)		1.389 (1.08–4.84)
Residual disease			<0.001		<0.001
≤1 cm	58	Referent		Referent
>1 cm	13	2.19 (1.59–4.43)		2.46 (1.89–4.16)
Mimitin expression			0.041		0.003
High	52	Referent		Referent
Low	19	2.11 (1.03–4.33)		3.96 (1.59–9.90)
14-3-3 ζ/δ expression			0.021		0.011
High	53	Referent		Referent
Low	18	2.29 (1.14–4.62)		2.88 (1.28–6.51)

Significant values appear in boldface type. P < 0.05 was considered to be statistically significant. CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.